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Norovirus immunity is poorly understood as the limited data available on protection after infection are often
contradictory. In contrast to the more prominent GII noroviruses, GI norovirus infections are less frequent in
outbreaks. The GI noroviruses display very complex patterns of heterotypic immune responses following
infection, and many individuals are highly susceptible to reinfection. To study the immune responses and
mechanisms of GI.1 persistence, we built structural models and recombinant virus-like particles (VLPs) of five
GI strains: GI.1-1968, GI.1-2001, GI.2-1999, GI.3-1999, and GI.4-2000. Structural models of four GI genotype
capsid P domain dimers suggested that intragenotype structural variation is limited, that the GI binding
pocket is mostly preserved between genotypes, and that a conserved, surface-exposed epitope may allow for
highly cross-reactive immune responses. GI VLPs bound to histo-blood group antigens (HBGAs) including
fucose, Lewis, and A antigens. Volunteers infected with GI.1-1968 (n  10) had significant increases between
prechallenge and convalescent reactive IgG for all five GI VLPs measured by enzyme immunoassay. Potential
cross-neutralization of GI VLPs was demonstrated by convalescent-phase serum cross-blockade of GI VLP-
HBGA interaction. Although group responses were significant for all GI VLPs, each individual volunteer
demonstrated a unique VLP blockade pattern. Further, peripheral blood mononuclear cells (PBMCs) were
stimulated with each of the VLPs, and secretion of gamma interferon (IFN-) was measured. As seen with
blockade responses, IFN- secretion responses differed by individual. Sixty percent responded to at least one
GI VLP, with only two volunteers responding to GI.1 VLP. Importantly, four of five individuals with sufficient
PBMCs for cross-reactivity studies responded more robustly to other GI VLPs. These data suggest that
preexposure history and deceptive imprinting may complicate PBMC and B-cell immune responses in some
GI.1-1968-challenged individuals and highlight a potential complication in the design of efficacious norovirus
vaccines.
Noroviruses are the second-most important cause of severe
viral gastroenteritis in young children and cause approximately
20% of endemic familial diarrheal disease and traveler’s diar-
rhea in all ages (reviewed in references 45 and 70). Noroviruses
are genetically grouped into five different genogroups (GI to
GV). GI and GII genogroups are responsible for the majority
of human infections and are subdivided into more than 25
different genotypes (for example, GI.1 is genogroup I genotype
1). Most norovirus outbreaks are caused by the GII.4 genotype
(65). Although genogroup I strains are associated with fewer
reported outbreaks, they are frequently identified in environ-
mental samples and in children (7, 21, 33, 58, 74, 82). The
severity of norovirus disease is usually moderate although in-
fection can be especially virulent, even fatal, in the elderly (14,
24, 31, 38, 46, 67). An effective vaccine would be particularly
advantageous to vulnerable older populations, food handlers,
child and health care providers, and military personnel. One
major obstacle to norovirus vaccine development is the lack of
understanding of the extensive antigenic relationships between
heterogenic norovirus family members and of how this anti-
genic heterogeneity affects host protective immunity. Norovi-
rus heterogeneity can be examined through sequence, struc-
tural, ligand binding, and host immune studies.
Structurally, noroviruses are 38-nm icosahedral viruses
with an 7.5 kb single-stranded, positive-sense RNA genome
that encodes three large open reading frames (ORFs). ORF1
encodes the replicase polyprotein, while ORFs 2 and 3 encode
the major and minor capsid proteins, respectively. The ORF2
major capsid protein sequence can vary by up to 60% between
genogroups and by 20 to 30% between the genotypes (91).
Expression of the major capsid protein (ORF2) in baculovirus
and Venezuelan equine encephalitis (VEE) results in forma-
tion of virus-like particles (VLPs) composed of 180 copies of
the monomeric protein (72). The monomer is structurally di-
vided into the shell domain (S) that forms the structural core
of the particle and the protruding domain (P) that protrudes
away from the core. The P domain is further subdivided into
the P1 subdomain (residues 226 to 278 and 406 to 520) and the
P2 subdomain (residues 279 to 405) (72). P2 represents the
most exposed surface of the viral particle and determines in-
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teraction with both potential neutralizing antibody recognition
sites and putative cellular receptors, the histo-blood group
antigens (HBGAs) (13, 16, 54, 57).
The P domain has been shown to independently form dimers
and P particles comprised of 12 monomers (85). Dimers and P
particles share structural and HBGA binding similarities with
the VLP generated with the same monomers (9, 85, 87). Three
norovirus-HBGA binding profiles have been identified: (i)
those that bind A/B and/or H epitopes, (ii) those that bind
Lewis and/or H epitopes, and (iii) those that do not bind any
available HBGA (86). Elegant structural analyses of Norwalk
virus VLPs in complex with synthetic HBGAs identified a highly
conserved binding site within the G1 noroviruses and predicted
that structural constraints within the GI strains would restrict
HBGA binding patterns to either a terminal Gal-Fuc or
GalNAc (18, 88).
Norwalk virus (NV; GI.1-1968) is the prototypic GI strain
and typically infects individuals who encode a functional FUT2
-1,2-fucosyltransferase enzyme resulting in expression of
HBGAs on mucosal surfaces (secretor-positive phenotype) (53).
Individuals who do not encode a functional FUT2 enzyme have
a secretor-negative phenotype, do not express ABH HBGAs
on mucosal surfaces, and are resistant to NV infection. Out-
break investigations have confirmed the association between
HBGA expression and norovirus infection for some GI and
GII strains (37, 39, 43, 49, 89). It remains likely that enzymes
other than FUT2 may function as norovirus susceptibility fac-
tors because secretor-negative individuals have low-level noro-
virus-reactive antibodies (49, 52, 53) and can become infected
after challenge with a GII.2 strain (52); in addition, some
norovirus strains bind to FUT2-independent HBGAs in vitro
(35, 54, 79).
Early challenge studies (reviewed in reference 50) suggested
that short-term protective immunity may occur following NV
challenge (96). Demonstration of long-term protective immu-
nity has been more complex. One early rechallenge study
found that 50% of NV-challenged volunteers experienced re-
peat infections after 3 years while the other 50% remained
well initially and after repeated challenge (69). Whether these
volunteers remained disease free because of acquired immu-
nity or genetic resistance could not be ascertained (69). How-
ever, contemporary norovirus challenge studies suggest that an
early mucosal IgA response is associated with protection from
NV infection (53). Further, strong gamma interferon (IFN-)
secretion from CD4 T cells (52) was identified in some un-
infected GII.2-1976-challenged volunteers.
In the absence of additional rechallenge studies, the most
compelling evidence for a long-term protective immune re-
sponse comes from the growing number of reports from
around the world indicating that periods of “high norovirus
activity” correlated with the emergence of new GII.4 strains (1,
10, 42, 66, 75, 90). Subsequently, the years following the high
activity were characterized by decreased numbers of outbreaks,
indicating that herd immunity may be an important regulator
of GII.4 noroviruses (54, 80, 81). Clearly, the molecular basis
for differential protective immunity/susceptibility following re-
peat norovirus infection is complex and a major challenge for
the field.
In this report, we compare the VLP phenotypes of the pro-
totypical norovirus strain NV to an extant GI.1 strain isolated
33 years after NV and to a panel of VLPs representing strains
GI.2, GI.3, and GI.4. In the results, we evaluate sequence
conservation, carbohydrate (CHO) binding patterns, and an-
tigenic relatedness at the antibody and T-cell levels. In con-
trast to earlier predictions (19), these data suggest that the
GI noroviruses can bind many different HBGAs and that in-
dividuals infected with norovirus usually mount robust B- and
T-cell responses against homologous strains. Surprisingly,
some individuals appear to preferentially mount immune re-
sponses against heterologous GI strains.
MATERIALS AND METHODS
Ethics statement. Archived serum samples were collected from individuals
infected with GI.1-1968 for an unpublished pilot study (C. L. Moe, unpublished
data) conducted with the volunteers’ written informed consent and with approval
from the IRBs at their respective institutions.
Phylogenetic analysis of the norovirus GI ORF2 sequences. At the time of this
study, 44 full-length and unique GI genotype capsid sequences were available at
NCBI, and these amino acid sequences were downloaded and included in a
collection with four of our own in-house sequences, for a total of 48 full-length
sequences (see Table S1 in the supplemental material). Additional sequences
were present but were identical to sequences selected in the final unique set. The
48 unique amino acid sequences were aligned by ClustalX, version 1.83 (17),
using the percent accepted mutation (PAM) distance matrix and default param-
eters (see Fig. S1 in the supplemental material). The alignment was refined
manually, and sites of variation, defined as any site with a quality score of less
than 100, were exported in table format and ordered by genotype. To eliminate
potential sequencing errors, positions that were different in only one represen-
tative sequence were removed. Variable sites that occurred in the P2 subdomain
were exported using Microsoft Excel.
Phylogenetic analysis was conducted using amino acid alignment to generate a
phylogenetic tree via Bayesian inference (BI) using Mr. Bayes, version 3.12 (76).
Briefly, the alignment was exported in the nexus format, the amino acid substi-
tution model was set to Dayhoff (22) using the lset command, and Markov chain
Monte Carlo simulation (27, 32, 36) was used to approximate the posterior
probabilities of trees, with sampling conducted on four chains over 500,000
generations (77). Trees were sampled every 100 generations, and the 5,001 trees
collected were summarized with the sumt command set to a burn-in of 1,000,
which generated a consensus tree using the 50% majority rule (77). The burn-in
value was determined using the sump command with an arbitrary burn-in of 250,
which demonstrated that stationarity occurred prior to the 100,000th generation,
indicating that a burn-in of 1,000 was appropriate for the sumt command (77).
Mapping informative sites onto the predicted structure. The X-ray crystal
structure of the P domain of GI.1 Norwalk virus in complex with H type 1-pen-
tasaccharide and A-trisaccharide (19) (Protein Data Bank [PDB] accession num-
bers 2ZL5, 2ZL6, and 2ZL7) was used as a template to generate comparative
homology models of each GI genotype sequence using the program 3D-Jigsaw
(3, 4, 20), with default parameters, and Modeler, version 8.2, using the auto-
model class (26, 60). Five models of each were generated, and the model with the
lowest objective function score was selected for analyses. The PDB files gener-
ated by these programs were visualized using the molecular modeling tools
MacPyMol (DeLano Scientific) and Chimera (71). In addition, the variation
measured in the multiple sequence alignment was mapped onto the Norwalk
VLP structure (PDB code 1IHM) using the program ConSurf, version 3.0, to
generate a structure highlighting the variable sites (47).
G1 VLPs. Capsid gene constructs for each strain were designed and synthe-
sized as reported previously (2, 54). Briefly, the ORF2 genes of GI.1-1968 (2),
GI.2-1999, GI.3-2000, and GI.4-2000 were derived from reverse transcription-
PCR (RT-PCR) products from outbreak stool samples (54, 92) while the ORF2
gene of GI.1-2001 (accession number AY502016) was synthesized commercially
by BioBasic (https://www.biobasic.com/index.php) (54). All ORF2 constructs
were then inserted directly into the VEE replicon vector for the production of
virus replicon particles (VRPs). VLPs were expressed in VRP-infected BHK
cells and purified by velocity sedimentation in sucrose, and approximately 35-nm
particles were visualized by negative-staining electron microscopy (EM) (2, 56).
VLP concentrations were determined by a Bio-Rad protein assay (Bio-Rad,
Hercules, CA) and 1 g/ml was used to coat enzyme immunoassay (EIA) plates,
bind HBGAs, and stimulate peripheral blood mononuclear cells (PBMCs).
Carbohydrate binding assays. VLP binding to HBGA-phenotyped boiled sal-
ivary samples and synthetic HBGAs was determined as reported previously by
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our group (52, 53) with the exception of the use of either mouse anti-VLP
antiserum (either strain-specific or cocktails) or rabbit anti-GI VLP polyclonal
serum, followed by anti-mouse/rabbit alkaline phosphatase (Sigma Aldrich, St.
Louis, MO) and p-nitrophenyl phosphate (pNPP; Sigma Aldrich) for VLP bind-
ing detection. Blockade experiments used H type 3 for GI.1-1968, GI.1-2001, and
GI.2-1999 and Lea for GI.3-1999 and GI.4-2000 HBGA ligands. VLP binding to
synthetic HBGAs was determined using NeutriAvidin-coated plates (Pierce,
Rockford, IL) treated with 10 g/ml biotinylated carbohydrate (Glycotech,
Gaithersberg, MD, and the Consortium for Functional Glycomics, grant number
GM62116) for 1 h and washed with phosphate-buffered saline (PBS)–0.05%
Tween 20 before the addition of 1 g/ml VLP for 1.5 h. VLP binding was
detected with rabbit anti-GI VLP polyclonal serum followed by pNPP. All incu-
bations were done at room temperature. The 50% blockade titer (BT50) was
defined as the reciprocal of lowest serum dilution tested that blocked at least
50% of binding compared to levels determined in the absence of antibody
pretreatment. Serum samples that did not reach a BT50 by the maximum percent
serum tested were assigned a BT50 value equal to the twice the maximum
percent serum tested for statistical analysis. Serum samples that blocked 50%
binding at the lowest percent serum tested were assigned a BT50 value equal to
one-half the minimum percent serum tested for statistical analysis (54).
Serum samples. Volunteers were determined to be infected with GI.1-1968 by
the sequence of the challenge inoculum and the presence of GI.1-1968 RNA in
any postchallenge stool sample or by seroconversion to GI.1-1968. Seroconver-
sion was defined as a 4-fold increase above prechallenge (day 0) titer in
postchallenge (day 14) samples (53). Geometric mean titers of VLP-reactive
serum IgG were measured by EIA (52–54). Briefly, plates were coated at 1 g/ml
VLP in PBS for 4 h at room temperature and blocked overnight at 4°C in 5%
Carnation dry milk in PBS–0.05% Tween 20 before the addition of serially
diluted serum. The serum was incubated for 1 h at 37°C before addition of mouse
anti-human IgG-alkaline phosphatase (Sigma Chemicals) for 30 min at 37°C and
color development with pNPP (Sigma Chemicals). Each step was followed by
washing with PBS–0.05% Tween 20, and all antibodies were diluted in 5%
Carnation dry milk in PBS–0.05% Tween 20. Anti-VLP serum IgG was com-
pared to a purified IgG (Sigma Chemicals) of known concentration for quanti-
fication. In this report archived plasma pairs obtained from 10 individuals in-
fected with GI.1-1968 in an unpublished pilot study (Moe, unpublished) are
characterized. Additional serum samples collected during a reported GII.2-1976
human challenge study (52) and a GII.4 outbreak (54) were used for compari-
sons.
VLP stimulation of PBMCs. The 10 infected volunteers who provided serum
samples also provided PBMCs collected prechallenge (day 0) and postchallenge
(days 4, 14, and 35). Cryo-preserved PBMCs were processed, aliquoted at 5 
105 cells/well, and stimulated with either 10 ng/ml phorbol myristate acetate
(PMA)–0.5 g/ml ionomycin, medium only, or 1 g/ml GI VLP for 48 h, as
described previously (52). Cell-free culture supernatants were collected and
stored at 20°C until evaluation of secreted IFN-. A significant percentage of
the volunteers (30%) did not have prechallenge samples for comparison. To
mitigate the impact of missing samples and of hyperactivation in a few select
archived samples, a more conservative definition was used for determining a
PBMC response. PBMCs were considered responsive to a VLP if two consecu-
tive postchallenge samples had a 4-fold increase above the earliest collected
sample (day 0 or day 4) (94).
Measurement of IFN- secretion. IFN- secretion was measured in duplicate
by EIAs (BD Biosciences), and the lower limit of detection was 4 pg/ml. Samples
below this limit were assigned a value equal to half the lower limit of detection
(2 pg/ml) for analysis purposes (52). For all samples, the medium-stimulated
background was subtracted.
Statistical analysis. IgG data were not normally distributed even after trans-
formations; thus, the Kruskal-Wallis test, followed by a posthoc Dunn’s multiple
comparison test (KW test), was used for comparisons of IgG and blockade
response between multiple groups. A Mann-Whitney two-tailed test (M-W test)
was used to compare IgG responses between two groups (52). P values of less
than 0.05 were considered significant.
RESULTS
GI sequence variation and phylogeny. Based on the nucle-
otide sequence of ORF2, the major capsid protein gene, geno-
group I noroviruses are currently subdivided into eight geno-
types (97). All eight genotypes were represented in the 48
full-length capsid amino acid sequences analyzed in this study.
Bayesian analysis, using a GII.4 sequence as an outgroup, was
used to generate a phylogenetic tree showing the evolutionary
relationships of these viruses (Fig. 1). In contrast to findings
reported among GII.4 noroviruses (54), sequence variation in
FIG. 1. Bayesian analysis of the GI genogroup. The 48 sequences of the GI genogroup were aligned and analyzed by Bayesian inference, which
demonstrated the evolutionary relationship between the eight genotypes. Only the reference sequences are shown, along with those sequences used
to generate VLPs, indicated in bold with an asterisk. Black boxes indicate genotypes. Scale bar, 0.1 substitutions per site.
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the tree occurred primarily between genotypes, with very little
variation identified within any specific genotype (Fig. 1).
Among these, the GI.3 genotype contained the most in-
tragenotype variation showing two distinct clades, labeled A
and B in Fig. 1. While variation occurred in the S domain and
the P1 subdomain of the capsid, the most significant changes
occurred in the P2 subdomain, consistent with results observed
in the GII.4 genotype (54). Based on available VLPs, our study
focused on the GI.1, GI.2, GI.3, and GI.4 genotypes. Analysis
of these GI sequences in the P2 subdomain region demon-
strated that significant variation occurred between genotypes
in this subdomain although several of the residues that interact
with the HBGAs (19) were strictly conserved within the GI
genogroup (Fig. 2 and 3), as previously reported (19, 83). Of
note, amino acids Gln353 and Asp355 (alignment numbering),
which are present in the GI.1 genotype, have been shown to
interact with the H type 1 pentasaccharide but not A trisac-
charide in a crystallography study of GI.1 Norwalk VLP (9, 19).
However, this motif was not conserved in the other GI noro-
viruses (9, 19), as Asp355 was present only in the GI.1 geno-
type sequences, which suggests that this negative charge may
regulate GI.1 HBGA binding. Additionally, residues at align-
ment positions 344 and 353 may also play a role in regulation
of carbohydrate binding (Fig. 2) as these sites are proximal to
the binding site and are variable in some genotypes. In fact,
S338 in the GI.1 genogroup (position 344 in the alignment) was
shown to interact with the A trimer via a water bridge hydro-
gen bond (9, 88), and altering the amino acid at this position,
as occurs in different genotypes, may result in differential HBGA
binding. Interestingly, nine sites in the P2 subdomain were
consistently different for each genotype, and these sites in-
cluded 331, 352, 354, 360, 362, 380, 383, 400, and 403 (Fig. 2),
using the alignment numbering as a reference.
Structural variation within the GI genotype. The Norwalk
virus protruding domain structure (PDB 2ZL5) was used to
generate homology models for genotypes: GI.2-1999 Southamp-
ton, G1.3-1999 Desert Shield, and GI.4-2000 Chiba sequences
(Fig. 3). Comparison of these structural models with the Nor-
walk structure indicated that, while the variation in the P2
subdomain region altered the overall structure, many of these
changes occurred away from the reported HBGA binding site
(19) (Fig. 4). Several residues that were reported to interact
with the HBGAs were strictly conserved (Fig. 4), and distal
variation was predicted to have a less direct, perhaps regula-
tory, effect on binding. Within the GI.1 Norwalk genotype,
variation between two isolates that were over 30 years apart
resulted in only minor structural changes in the P2 subdomain
as only five changes occurred in the P2 subdomain during this
period. Of these five changes, only the change of Asp to Glu at
position 361 of the multiple alignment (position 350 of Nor-
walk capsid) is predicted to result in minor structural differ-
ences on the surface of the capsid (Fig. 4A). Other changes
within the genotype resulted in insertions of loops that ex-
tended to or beyond the surface (Fig. 4). In fact, GI.2, GI.3,
and GI.4 models all had inserted loops that resulted in struc-
tural differences in the P2 subdomain while generally main-
taining the topology of the HBGA binding pocket and intro-
ducing variation in the ridges surrounding the binding site
(Fig. 4).
Analysis of the structure and mapping of the variation and
insertions/deletions on the dimer models revealed that the
variation that has occurred in the P subdomain between the
different genotypes occurs primarily away from the binding
site. Interestingly, a distinct conserved region that might in-
clude important epitopes for antibody recognition was identi-
fied in all four of the GI structures that we analyzed (Fig. 4).
This region occurs distal to the binding site, and most of the
conserved residues are surface exposed (Fig. 4). These con-
served, surface-exposed residues may represent a common an-
tibody epitope, conserved among the GI genogroup and per-
haps facilitating the generation of cross-reactive antibodies
FIG. 2. Variation in the P2 subdomain of the first four GI genotypes. Variation within the P2 subdomain of eight GI.1 to GI.4 representative
sequences is shown with the genotype-specific changes colored as follows: GI.1 Norwalk, red; GI.2 Southampton, blue; GI.3 Desert Shield, green;
and the GI.4 Chiba, purple. Amino acids that occur within multiple genotypes on one occurrence (yellow) and multiple occurrences (orange) are
shown. Unique differences that occur within a genotype are indicated by a lighter shade of the primary genotype color. Position numbers filled in
gray indicate residues that interact with HBGAs in the GI.1 Norwalk capsid, and columns that are shown in gray indicate residues that are strictly
conserved within these four genotypes. Alignment indicates numbering based upon the multiple alignment, and Norwalk indicates numbering
based upon the GI.1 Norwalk sequence. Representative sequences were selected to demonstrate the sequence heterogeneity within the genotype.
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against multiple GI noroviruses, as has been described in the
literature (6, 44, 51).
VLP production and characterization. Genotypes GI.1, GI.2,
GI.3, and GI.4 were available for VLP production to compare
the antigenic relationship between GI genotypes. Across the
genotypes, the capsid sequences share similarities ranging
from 65 to 75%. To compare the antigenic relationship within
a genotype, an additional GI.1-2001 VLP was prepared to
compare it to GI.1-1968. Even with 30 years between collection
dates of these isolates, the capsid sequences of GI.1-1968 and
GI.1-2001 strains are 98% similar. All clones were confirmed
to produce appropriately sized VLPs by electron microscopy
before being characterized for carbohydrate binding ability
and antigenicity.
Carbohydrate ligands were determined by binding to pheno-
typed saliva and to biotinylated synthetic HBGAs (54). All of the
GI VLPs had preferential binding to secretor-positive, O and A
blood type saliva, with more modest binding to B blood type saliva
FIG. 3. Structural comparison between the Norwalk P domain structure and GI genogroup models. Homology models were generated for
GI.1-2001, GI.2-1999, GI.3-1999, and GI.4-2000 P domain sequences using chain A and chain B of the Norwalk P domain dimer structure, and
these were compared. In all cases, the residues reported to interact with the HBGAs were conserved (magenta). Chain A of each model is shown
in the brighter shade on the left, and chain B is shown as the lighter shade on the right. Magenta indicates the binding pocket. (A) Norwalk crystal
structure with the H type 1 pentasaccharide shown engaging with the receptor binding pocket. (B) The GI.2-1999 Southampton model shows that
inserts have added loops to the top of the structure, which extends from the surface adjacent to the conserved binding pocket. (C) The GI.3-1999
Desert Shield model is structurally similar to that of the Norwalk structure, with a conserved receptor-binding pocket. (D) The GI.4-2000 Chiba
model is also structurally similar to the Norwalk structure, with a conserved receptor-binding region.
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at room temperature (Fig. 5). Low levels of binding to B blood
type saliva are detected at room temperature but not 37° (data not
shown), supporting previous reports of temperature-dependent
VLP-ligand interaction (54, 78). GI.2-1999, GI.3-1999, and GI.4-
2000 also bound to secretor-negative, Lewis-positive saliva.
Neither of the GI.1 VLPs bound to secretor-negative saliva.
Binding to synthetic biotinylated HBGAs confirmed these
binding patterns (Fig. 6). Carbohydrate binding profiles be-
tween the two GI.1 VLPs was very similar. The GI.1 VLPs
bound to FUT2-dependent molecules H type 1, H type 3, and
A trimer, as previously reported (34, 53, 59). The other GI
VLPs all bound to FUT2 and or Lewis-dependent carbohy-
drates. GI.2-1999 bound to H type 3 and Lea, GI.3-1999 bound
only to Lea, and GI.4-2000 bound to Lea, Lex, and A trimer,
supporting the novel observation of these GI VLPs binding to
both secretor-negative and secretor-positive salivary samples.
NV infection induces a GI broadly reactive antibody re-
sponse. Previous studies have indicated that the GI strains
FIG. 4. Structural differences between the Norwalk P domain structure and the GI genogroup models. Analysis of the homology models in
comparison to the Norwalk P domain dimer structure demonstrated that much of the variation in the genogroup occurs in loops that extend to
the surface. Red indicates a conserved structural domain, purple indicates the binding pocket, and yellow indicates variation within the genotype.
(A) The variation over 30 years within the GI.1 genotype resulted in only minor structural differences. The only observed change was a change of Asp
to Glu at Norwalk capsid position 350 (arrow). (B) The GI.2-1999 Southampton genotype mostly differs from GI.1 by the addition of several residues
that occur in loops shown in green. (C) The GI.3-1999 Desert Shield genotype mostly differs from GI.1 by the addition of residues in loops shown in
brown. (D) The GI.4-2000 Chiba genotype mostly differs from GI.1 by the addition of only a few residues that occur in loops shown in orange.
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share common antibody epitopes (25, 29, 68). The P2 domain
is the most surface exposed part of the capsid, and antibody
neutralization epitopes in noroviruses have been mapped to
this region (57). An EIA was used to compare the antigenic
relationship between NV GI.1-1968 and our panel of GI VLPs
from 10 NV GI.1-1968-infected volunteers by using archived
prechallenge (day 0) and convalescent-phase (day 14) sera.
The percentage of subjects who had a 4-fold increase between
prechallenge and convalescent-phase serum samples (serocon-
verted) to each VLP and the median titer and range of pre-
challenge and convalescent-phase serum samples to each VLP
are shown in Fig. 7. Prechallenge IgG titers were similar across
the panel of VLPs (median, 10.5, 16.6, 30.6, 43.2, and 21.8
g/ml for NV GI.1-1968, GI.1-2001, GI.2-1999, GI.3-1999, and
GI.4-2000, respectively). NV infection resulted in a significant
increase in GI VLP-reactive IgG between prechallenge and
convalescent-phase sera for all VLPs tested (P 	 0.01, M-W
test). Convalescent IgG titers were also similar between each
VLP (median, 460.6, 452.3, 216.3, 614.0, and 389.5 g/ml for NV
GI.1-1968, GI.1-2001, GI.3-1999, and GI.4-2000, respectively).
Nine out of the 10 infected volunteers seroconverted to all five
GI VLPs. The one exception was positive for GI.1-1968 RNA
in multiple stool samples but did not seroconvert to any GI
VLP except GI.2-1999. Prechallenge anti-GI VLP titers in this
individual ranged from 47 times the group median for GI.1-
1968 to 2.5 times for GI.2-1999. The elevated prechallenge
titers were 496.2, 277.5, 75.3, 500.4, and 169.9 g/ml for NV
GI.1-1968, GI.1-2001, GI.3-1999, and GI.4-2000, respectively.
NV-induced IgG blocks ligand binding of multiple GI VLPs.
The high degree of serum cross-reactivity among the GI VLPs
indicates that these strains share either many common or one/
few immunodominant antibody epitopes. In the absence of a
cell culture system for human norovirus cultivation, a surrogate
assay for antibody-mediated neutralization was developed to
evaluate this cross-reactive IgG in a functional assay. The
blockade assay measures the ability of antisera to block the
interaction of a VLP with a carbohydrate ligand (30, 54, 56).
Although prechallenge serum samples reacted with each GI
VLP, as a group they did not efficiently block the binding of
any of the GI VLPs to HBGA. The dilution of serum needed
to block 50% of binding (BT50 value) for each VLP was at or
below the minimum dilution tested (BT50 of 400) (Fig. 8A).
Binding of GI.4-2000 to HBGA was moderately inhibited in a
nonspecific way, as evidenced by a decreased signal at all con-
centrations studied without a dose dependence (Fig. 8A). Each
volunteer had a unique prechallenge GI VLP blockade profile.
Only two volunteers had detectable BT50s for GI.1-1968 in
prechallenge serum (volunteers 09 and 10) (Fig. 9). These
volunteers also had a prechallenge blockade antibody to the
other GI VLPs. Volunteer 08 had prechallenge titers to GI.1-
2000 and GI.3-1999.
Regardless of prechallenge anti-NV GI.1-1968 IgG or block-
ade titer, GI.1-1968 infection resulted in an increased blockade
ability for all five GI VLPs. As a group, convalescent-phase
sera (n 
 10) effectively blocked GI.1-1968 interaction with H
type 3, as well as GI.1-2001 and GI.2-1999 interaction with H
type 3 and GI.3-1999 and GI.4-2000 interaction with Lea (Fig.
8B). The median BT50 serum dilution needed to block GI
VLP-HBGA binding was 400 for GI.1-1968, which is similar to
the BT50 for blockade of GI.1-2001 (1,067), GI.2-1999 (2,139),
GI.3-1999 (800), and GI.4-2000 (1,081) (P 0.05, KW test)
FIG. 6. GI VLP-carbohydrate binding patterns at room tempera-
ture. VLPs were assayed for the ability to bind to synthetic biotinylated
HBGA bound to avidin-coated plates. The mean optical density (OD)
is indicated by the line in the box. The upper and lower boundaries of
the box represent the maximum and minimum values. (A) VLP bind-
ing to core chains including an -1,2-fucose. (B) VLP binding to either
core chains or H antigens modified with the Lewis antigen. (C) VLP
binding to A or B antigen trimer.
FIG. 5. GI VLP-salivary binding patterns at room temperature. GI
VLPs were assayed for ability to bind to saliva samples phenotyped for
secretor status (Se) and ABO blood type by EIA. OD, optical density.
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(Fig. 8C).While BT50s were not statistically different between
the VLPs, for all volunteers blockade of GI.1-1968 required
more serum than blockade of the other GI VLPs. This differ-
ence is independent of HBGA binding signal strength as it
holds for GI.1-2001 and Chiba (both equally strong HBGA
binders compared to GI.1-1968) and GI.2-1999 and GI.3-1999
(both relatively weak HBGA binders). As demonstrated in
prechallenge serum samples, each volunteer had a specific
VLP-HBGA blockade profile. After infection, 9 out of 10
volunteers had a sufficient BT50 for GI.1-1968. Further, all of
these nine volunteers also had a BT50 for the other four GI
VLPs after GI.1-1968 infection. The one volunteer who did not
produce a BT50 to either of the GI.1 VLPs did raise a sufficient
BT50 (BT50 of 400) to GI.2-1999 and GI.3-1999 (Fig. 9,
volunteer 01). Blockade of GI.2-1999, GI.3-1999, and GI.4-
2000 varied by volunteer, as shown in Fig. 9. These data indi-
cate that the GI VLPs share potential cross-neutralization
epitopes. This cross-neutralization potential may be unique to
the GI strains as neither NV GI.1-1968 serum nor GII.2-1976
serum blocked interaction of GII.4-1997 VLP with H type 3
(54) (BT50 of 200 for both serum sets) (Fig. 10).
NV infection induces a GI broadly reactive T-cell response.
Although previous studies of immunity in NV-infected volun-
teers have focused exclusively on antibody responses (37, 53),
cellular immune responses are also likely to be important com-
ponents of protective immunity. In support of this hypothesis,
PBMCs from volunteers challenged with GII.2-1976 demon-
strated significant IFN- secretion from CD4 T cells after
GII.2-1976 VLP in vitro stimulation (52). To initially charac-
terize the cellular immune response after NV infection,
PBMCs were isolated from whole blood collected from NV-in-
fected volunteers (n 
 10) and cryo-preserved for in vitro VLP
stimulation and secreted IFN- analysis by EIA. All PBMC
samples responded to PMA-ionomyosin stimulation with levels
of IFN- secretion above the upper limit of detection (data not
shown), indicating that the cell populations remained respon-
sive after harvesting. As a group, the 10 volunteers did not have
a significant response to stimulation with any of the GI VLPs
at day s 4, 14, or 35 postchallenge compared to prechallenge
responses (data not shown). However, individually, PBMCs
from 6 of the 10 volunteers did respond with IFN- secretion
to at least one GI VLP stimulation (Fig. 11). Three volunteers
did not have prechallenge samples for comparison. Therefore,
PBMCs were considered responsive to a VLP if two consecu-
tive postchallenge samples had a 4-fold increase above the
earliest collected sample (day 0 or day 4) (94). Interestingly,
only two volunteers’ PBMCs responded to GI.1 VLP (volun-
teers 09 and 10). These two volunteers also had higher pre-
challenge anti-GI.1 IgG and blockade titers. Of note, volunteer
10 had insufficient PBMCs for heterologous VLP stimulation;
thus, potential cross-VLP responses were not determined.
Three volunteers each responded to only one GI VLP, with
one responder each to GI.2-1999, GI.3-1999, and GI.4-2000.
The remaining volunteer responded to both GI.2-1999 and
FIG. 7. GI VLPs share common antibody epitopes. The median
geometric mean titer of anti-VLP IgG (g/ml) in prechallenge (day 0;
dotted bars) and convalescent (day 14; shaded bars) serum samples
collected from volunteers infected with GI.1-1968 and the number of
subjects who seroconverted to each VLP were determined. The me-
dian titer is indicated by the line in the box. The upper and lower
boundaries of the box represent the maximum and minimum values.
The asterisk indicates a significant increase (P 	 0.01, M-W test) in
titer between day 0 and day 14 samples.
FIG. 8. Cross-blockade of GI VLPs binding to HBGA by GI.1-1968
convalescent-phase serum. Serum samples collected from GI.1-1968-
infected volunteers were assayed for blockade of H type 3 interaction
with GI.1-1968, GI.1-2001, and GI.2-1999 and Lea interaction with
GI.3-1999 and GI.4-2000, and the median percent control binding was
calculated relative to the no-serum control binding. (A) Prechallenge
serum. (B) Day 14 convalescent serum. (C) Scatter plot of the median
percent serum needed for BT50 and the number of volunteers with a
BT50 for each VLP (indicated below the graph). The median titer is
indicated by the line in the box. Error bars represent the range.
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FIG. 9. GI VLP blockade responses vary by individual. Serum samples collected from GI.1-1968-infected volunteers at day 0 (prechallenge;
left-hand column) and day 14 (right-hand column) were assayed for blockade of H type 3 interaction with GI.1-1968, GI.1-2001, and GI.2-1999
and Lea interaction with GI.3-1999 and GI.4-2000, and the percent control binding was calculated relative to the no-serum control binding.
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FIG. 9. —Continued.
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GI.3-2000. These data indicate that in 66% of the GI.1-1968-
infected volunteers, the cellular immune response is preferen-
tially targeting an alternative GI VLP rather than the infecting
strain.
DISCUSSION
Noroviruses are a leading cause of acute infectious gastro-
enteritis (45) and cause an estimated 23,000,000 infections
annually in the United States (61). Although the majority of
reported norovirus outbreaks are associated with the GII.4
strains, GI strains are more frequently detected in environ-
mental monitoring studies, indicating that these strains are also
circulating in the general population although disease patterns
in the young and in settings of endemicity are less well under-
stood (7, 21, 33). The fundamental mechanisms underlying
frequency, severity, and/or susceptibility to repeat infection
with GI and GII strains remains largely unknown, complicating
vaccine design and our understanding of evolutionary and ep-
idemiologic factors affecting disease occurrence and distribu-
tion in human populations. The continued prominence of the
GII.4 strains has been attributed to evolution within the P2
subdomain of these strains that leads to receptor switching and
antigenic drift, resulting in both access to previously resistant
populations and evasion of protective immunity in previously
susceptible populations (23, 54). Molecular mechanisms gov-
erning continued persistence of other noroviruses in human
populations are not well understood.
Bioinformatic analysis of the GI genogroup indicated that
evolution within the different GI genotypes induced only minor
effects on the capsid structure, which is in agreement with work
conducted by Choi et al. that showed the HBGA binding sites
were conserved between GI genotypes (19). The only GI ge-
notype that contained divergent evolution was the GI.3 Desert
Shield genotype, which clustered into two subclades with very
little divergence within them (Fig. 1). Although this may reflect
more limited sampling of the genogroup 1 biota and less se-
quence information available for analysis, these findings are in
stark contrast to the GII genogroup, where many genotypes
can be further subdivided into clusters that evolve from one
another. For example, a recent bioinformatics study of GII.2
strains suggested that this genotype may be evolving new
strains in a time-ordered manner over a 12-year period. It
appears that the novel strains were defined by targeted varia-
tion at select residues within the capsid sequence (40). This
variation primarily occurred in the surface-exposed P2 subdo-
main, suggesting that heterogeneity in the GII.2 strains was
mediated by an immune response-driven evolution (40). In
addition, similar studies with the GII.3 and GII.4 genotypes
show evidence of immune response-driven evolution (12, 54).
In contrast, the primary outcome of evolution in the GI
genogroup appears to be the formation of different genotypes
that appear to be antigenically and structurally static. Support-
ing this conclusion, bioinformatic analyses of the GI.1 strains
spanning 40 years did not reveal any significant evolutionary
trends over time (Fig. 1 and 2). The capsid sequences of NV
GI.1-1968 and GI.1-2001 are 97% similar to each other and
encode only five changes within the P2 subdomain between
these strains. Only one of these changes was surface exposed
(D350E, Norwalk numbering) (Fig. 2) and noticeably alters the
structure (D350E, Norwalk numbering) (Fig. 4). None of these
changes appears to be involved in HBGA binding as GI.1-1968
and GI.1-2001 have identical carbohydrate binding profiles,
with both strains dependent upon a Gal-Fuc or GalNAc for
binding. This limited binding phenotype is not conserved
across the GI strains as GI.2, GI.3, and GI.4 each bound to
Lea, a FUT2-independent HBGA, suggesting that the FUT2
gene may not be a susceptibility allele for all GI strains (39,
53). Binding of the -(1,3/4)-fucose of Lea and to secretor-
negative, Lewis-positive saliva by three of the four GI geno-
types argues that the recently reported (19) predicted universal
rules governing GI-HBGA epitope binding do not fully cap-
ture the phenotypic variation in HBGA binding patterns noted
among different GI VLPs. These predictions, based on the
structure of NV GI.1-1968 interaction with H type 1 and A
trimer, argue that structural constraints within the GI strains
will restrict HBGA binding patterns to either a terminal
Gal-Fuc or GalNAc. Importantly, the binding site identified
in the GI.1 crystallography study was almost entirely con-
served in the structural models of the other GI genotype
structures, with the 327-DXH-(X)48-WXSXXS-380 portion
(Norwalk numbering) being strictly conserved (Fig. 2) in the
GI.1 through GI.4 genotypes. This suggests that all four of the
GI VLPs that we analyzed may utilize this binding site, but
FIG. 10. GI.1-1968 convalescent-phase serum does not block cross-
genogroup GII.4-1997 VLP binding to HBGA. (A) Convalescent-
phase serum samples collected from individuals infected with GI.1-
1968 (circles), GII.2-1976 (squares), and GII.4 (triangles) noroviruses
(n 
 6 each strain) were assayed for blockade of GII.4-1997–H type 3
interaction, and the median percent control binding was calculated
relative to the no-serum control binding. Error bars represent the
range. (B) Scatter plot of the median percent serum needed for BT50
for blockade of GII.4-1997–H type 3 interaction. The median titer is
indicated by the line in the box. Error bars represent the range. Serum
BT50 responses significantly different (P 	 0.05, KW test) from GI.1-
1968 blockade are marked with an asterisk.
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variations in HBGA recognition may be due to the changing
residue patterns in contact interface residues at positions 344,
353, 355, or, to a lesser extent, 395 (alignment numbering) or
by other varying residues that compose the extended pocket
around the HBGA binding sites. In addition, variation between
these genotypes suggests that surface-exposed charge changes
may be an important factor for determining which HBGAs can
bind without steric hindrance. Moreover, a recent report has
suggested that the HBGA binding site may be conformational
in nature, allowing target CHOs to fit into the structure rather
than utilizing the same linear sequences for interactions (88),
and therefore varying the residues distal to the binding site
may be important for allowing the structural flexibility neces-
sary for ligands to fit into the conformational pocket. Our data
certainly support this possibility and argue for the need for
solving additional GI VLP-CHO costructures.
FIG. 11. GI.1-1968 infection induces GI-reactive PBMCs collected from volunteers infected with GI.1-1968 were stimulated individually with
a panel of GI VLPs and IFN- secretion measured by EIA on days 0, 4, 14, and 35 postchallenge. Only VLPs with two consecutive time points
with elevated IFN- secretion levels are shown for each volunteer.
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While this study focused primarily on the P2 subdomain of
the capsid protein, additional variation in the P1 subdomain
could also contribute to differences in CHO binding, as has
been suggested for GII.4 noroviruses (13, 54). Not only are
crystal structures of additional GI VLPs bound to HBGA li-
gands needed to address these questions, but also detailed
capsid mutagenesis studies may provide a means of determin-
ing the mechanisms governing variant HBGA recognition pat-
terns in the GI noroviruses.
GI noroviruses display very complex patterns of heterotypic
immune responses following infection, and many individuals
are highly susceptible to reinfection. Previous studies have
shown that anti-norovirus IgG is cross-reactive within a geno-
group but much less between genogroups (41, 52, 64). Our
results corroborate these findings (76). Using a standard VLP
antigen EIA, IgG elicited by NV infection showed a high
degree of reactivity to the panel of GI VLPs and a 4-fold
increase in titer between prechallenge and convalescent sam-
ples for each VLP. Mechanistically, this may result from the
following: (i) GI.1 infection may induce high-affinity antibodies
with strong heterotypic strain targeting; (ii) GI.1 infection may
induce preexisting memory B cells that secrete antibody with
low affinity to NV, but higher affinity to other GI strains; or (ii)
a conserved, surface-exposed region of the capsid protein nec-
essary for capsid function may provide a common epitope to
which cross-reacting antibodies bind.
This confirmation of cross-reactivity among GI clusters has
several implications. First, coupled with the data demonstrat-
ing that GI strains bind to FUT2-independent molecules, the
cross-reactivity provides an explanation for previously reported
observations that secretor-negative volunteers have serum an-
tibodies that react to NV GI.1-1968 (49, 52, 53). Second, the
high degree of cross-strain reactivity emphasizes the limitation
of using VLP antigens in antibody detection antigen EIAs as
diagnostic tools in outbreak investigations. While a 4-fold
increase in anti-VLP titers between acute and convalescent
samples is predictive of norovirus infection (52, 53), there was
not a significant difference between mean prechallenge or con-
valescent IgG titers in a comparison of the response to NV
GI.1-1968 to any of the other VLPs. These data support pre-
vious findings of a high degree of antibody cross-reactivity
between GI strains (64) and emphasize that the determination
of an outbreak strain by EIA reactivity to a limited panel of
VLPs is imprecise. Third, the data suggest that even an ex-
panded panel of VLPs may not be able to do more than
differentiate between a norovirus genogroup I versus II infec-
tion. This is an important issue in the context of outbreak
investigation, where we have found subjects to be more willing
to donate serum than stool samples for analysis and longitu-
dinal epidemiological studies that use sera collected over time
to draw conclusions about the epidemiology of endemic noro-
virus infections (84). Lastly, these data also suggest that con-
served antigenic epitopes among GI strains likely exist, arguing
for the need for the development of comprehensive monoclo-
nal antibody panels for epitope mapping.
In contrast to the VLP EIA, we have shown that the anti-
body blockade of the VLP-HBGA assay (30) is able to dis-
criminate antigenic differences between different strains of
GII.4 noroviruses (54). Surprisingly, this high degree of strain
specificity was not observed for the GI strains, where human
convalescent antisera cross-blocked not only different strains
within the same genotype but also strains between different GI
genotypes. This observation supports structural analysis indi-
cating that the GI strains lack the significant heterogeneity in
the P2 domain observed in GII.4 strains (19, 54). Even though
the prechallenge sera had reactive IgG to each of the GI VLPs
by EIA, the prechallenge sera from 8 out of 10 volunteers was
not able to block the interaction of any of the VLPs with
HBGA, possibly because of insufficient titer or lack of binding
site specificity. However, with one exception, after NV GI.1-
1968 infection, serum IgG was capable of blocking VLP-
HBGA binding for each GI VLP. Similar concentrations of
serum were needed to block all five GI VLPs binding to
HBGA, indicating that infection with GI.1-1968 may result in
production of potentially cross-genotype neutralizing antibody.
Additional antibodies with protective potential are likely to be
present in polyclonal sera. It is likely that protection from
infection is not solely dependent upon antibodies capable of
inhibiting the VLP-HBGA interaction. Further study of anti-
body epitopes and of the role of soluble capsid protein in
antibody interactions is needed. Although as a group the sera
blocked all of the GI VLPs tested, each volunteer exhibited a
distinct pattern of strain blockade. This variable pattern of
neutralization is similar to that identified in humans vaccinated
with strains of influenza virus where neutralizing antibody re-
sponses varied by individual, with all developing a neutralizing
antibody response but some developing greater increases in
neutralization titer to strains other than the vaccination strain
(8, 28, 73).
Overall, little information is available regarding the role of T
cells in norovirus infection. Initial characterization of the GII
norovirus-induced T-cell response identified a predominantly
Th1 CD4-dependent cellular response characterized by signif-
icant IFN- secretion (52). This study supports these findings
with a GI norovirus strain as IFN- was secreted in significant
amounts after NV GI.1-1968 infection in most volunteers. Six
out of 10 of the infected volunteers with PBMC sample sets for
analysis responded to in vitro stimulation to at least one GI
VLP. Surprisingly, only two had a 4-fold increase in IFN-
production between early and late PBMCs in response to GI.1
stimulation (85- and 200-fold increase above baseline compar-
ator) in contrast to results shown for PBMCs collected after
GII.2-1976 infection, where five out of seven infected volun-
teers responded to homologous VLP stimulation (median fold
increase above baseline, 33.2). Further, detected overall IFN-
secretion levels were lower in this study (median fold increase
of peak, 148.4 pg/ml compared to 1,418 pg/ml in GII.2-1976-
infected volunteers). Possible explanations for this observation
included timing of the postchallenge sample collection (days 0,
8, and 21 for the GII.2-1976 study compared to days 0, 4, 14,
and 35 here), and timing of postsample processing (immedi-
ately after blood collection compared to 24 h after collection
with shipment at uncontrolled temperatures in the intermedi-
ate). In particular, the delay required for shipment has been
demonstrated to reduce PBMC activity (11). Importantly, four
out of five volunteers with sufficient PBMCs for cross-reactivity
studies responded more robustly to other GI VLPs. This broad
PBMC response pattern is indicative of the response to cross-
reactive epitopes presented under different human leukocyte
antigen (HLA) backgrounds.
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Both the PBMC reactivity and antibody blockade data indi-
cate that complex patterns of adaptive G1 cross-reactive im-
mune responses may provide some level of cross-protection.
Moreover, data demonstrating that both antibody and T-cell
responses of some volunteers are skewed away from the in-
fecting strain and directed toward other GI strains reveal a
potential mechanism of deceptive imprinting (original anti-
genic sin [OAS]), suggesting that complex preexposure histo-
ries may complicate GI immune responses and allow for repeat
infections, which highlights a potential complication in the
design of efficacious norovirus vaccines. The skewed B-cell
responses in some of the GI.1-1968-infected volunteers may be
explained by two mechanisms. In the first mechanism, memory
cells may generate antibodies to the current challenge strain
that are also cross-reactive with other strains. A pan-anti-GI
antibody response would explain the high degree of IgG cross-
reactivity and blockade between the strains but not the differ-
ence in blockade between the strains for individuals. The sec-
ond mechanism, the concept of OAS, can explain both of these
observations and has been described both in mice (5, 48) and
in humans (62, 93) at the antibody and T-cell levels although
this is controversial (95) as it represents a highly variable re-
sponse regulated by complex antigenic relationships, host ge-
netics, and population exposure histories. OAS is a host-me-
diated response that induces memory cells to produce antibody
to a previous, similar, infecting pathogen instead of generating
a primary response to a slightly antigenically different, current,
infecting pathogen. OAS results in the production of lower-
affinity antibody and T cells for the current infection than what
would be produced as the result of a primary immune response
(63). An OAS effect depends upon an individual’s epitope
presentation and, thus, HLA type, the current infecting strain,
and exposure history to other strains (5, 63). While speculative,
these factors, and the complex antigenic interactions between
strains, may result in either cross-protection or attenuation of
protective immune responses as a function of prechallenge
exposure histories. Evidence of both skewed B- and T-cell
responses in some GI.1-1968-infected volunteers highlights the
need for continued human challenge studies both to unravel
the complex norovirus immune response and to evaluate
norovirus infection as a potential model system for study of OAS.
Early human NV GI.1-1968 rechallenge studies (69, 96)
have suggested three potential outcomes to NV rechallenge:
resistance to infection on the first and subsequent challenge,
development of protective immunity after infection, and re-
peated susceptibility to infection. Our contemporary NV GI.1-
1968 challenge study demonstrated that about 20% of chal-
lenge volunteers are secretor-negative individuals who lack
FUT2 and are genetically resistant to NV GI.1-1968 infection
(53). We also identified about 40% of the susceptible secretor-
positive individuals who remained uninfected even after high
doses of NV GI.1-1968 challenge (53). An early mucosal IgA
response was associated with these uninfected susceptible vol-
unteers, indicating that a protective anti-norovirus immune
response to NV GI.1-1968 infection might occur following
exposure in some individuals. Although additional studies are
needed, the work presented in this report suggests that the
third group of volunteers, those who are susceptible to repeat
NV GI.1-1968 infection, may be unable to mount robust pro-
tective immune responses because of preexposure biases and
OAS. The existence of this group of individuals has been cited
in the literature as proof that long-term protective immunity to
norovirus infection is not possible, a hypothesis in conflict with
data gathered in contemporary NV GI.1-1968 (53) and GII.2-
1976 (52) challenge and outbreak investigations (80, 81). Al-
though speculative, these studies provide one possible expla-
nation of why some volunteers can become repeatedly infected
with NV GI.1-1968 (69, 96). Although correlation with human
disease is unknown, new studies with mouse norovirus (MNV)
indicating that infection with high but not low levels of MNV
results in a lack of protective immunity (55) suggest the pos-
sibility of altered immune regulation following some norovirus
infections.
We have articulated a potential model to explain the vari-
able immune responses and susceptibility patterns noted fol-
lowing GI.1 infection, recognizing that this model is largely
based on descriptive findings following challenge with an 40-
year-old norovirus isolate. It is not clear whether challenges
with contemporary GI.1 isolates will reflect these infection
outcome patterns or whether similar findings would occur fol-
lowing challenge with other isolates. However, given the re-
markable stability of GI strains demonstrated here, these find-
ings are likely applicable to contemporary strains. The model
clearly defines a need for additional GI and GII rechallenge
studies that exclude genetically resistant volunteers and use
modern diagnostic assays, such as the antibody VLP-HBGA
blockade, large panels of GI and GII VLPs, the isolation of
human monoclonal antibodies following infection, and a vari-
ety of T-cell assays, to empirically determine the underlying
mechanisms governing variant GI.1-1968 infection outcomes
and to evaluate the hypothesis that OAS may induce the im-
mune response toward other norovirus strains. Further studies
should include higher numbers of infected and uninfected vol-
unteers and consider comparing antibody and T-cell responses
to antigens outside the major capsid protein as well as alter-
native measures of virus neutralization besides receptor block-
ade if a cell culture system for noroviruses becomes available.
Given the strict requirements for human challenge studies, the
gnotobiotic pig model for human norovirus GII.4 infection
may also serve as an important model and/or provide critical
information about strain cross-reactivity and cross-protection
(15, 83). However, human rechallenge studies remain key to
understanding the fundamental mechanisms governing suscep-
tibility to and frequency of norovirus infection.
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